-
Cyclosporin Variants: Structure and Mitochondrial Activity
2026-09-08
The 2020 reference study combined NMR spectroscopy, molecular dynamics, and calcium-dependent mitochondrial swelling assays to compare cyclosporins B–E with cyclosporin A. Its central finding was that three variants retained cyclosporin A-like inhibition of mitochondrial pore opening, whereas the structurally more rigid cyclosporin E was inactive at the tested concentrations, linking peptide flexibility with membrane-associated biological activity.
-
MK 0893 Workflow for GCGR Antagonism
2026-09-08
MK 0893 is a potent, reversible glucagon receptor antagonist for connecting GCGR binding, cAMP signaling, and glucose control in one research workflow. This guide translates its allosteric mechanism into practical cell-based, selectivity, and in vivo study designs with troubleshooting checkpoints.
-
Pronase E: From Digestion to Mechanistic Evidence
2026-09-07
Pronase E is a broad-spectrum protease mixture for converting complex protein samples into interpretable molecular evidence. This guide develops an assay-decision framework linking Pronase E sample preparation with mechanistic interpretation of the CUL3–MTDH ferroptosis pathway in triple-negative breast cancer research.
-
Urolithin A for Mitochondrial Quality Control
2026-09-05
Build a practical Urolithin A workflow that connects mitophagy, respiratory function, and metabolic remodeling with fibrosis-oriented assay design. The guide separates evidence-supported findings from hypothesis-generating applications, with dosing, controls, and troubleshooting for reproducible cell studies.
-
Palomid 529: A Pathway-Aware Assay Strategy
2026-09-05
Palomid 529 (P529) offers a distinctive way to test whether PI3K/Akt/mTOR signaling sustains ESCC metastasis and treatment resistance. This guide translates RCN2 mechanistic findings into rigorous pathway, angiogenesis, cisplatin, and radiotherapy assay decisions.
-
ATRX Deficiency Sensitizes Glioma to PDGFR Inhibitors
2026-09-04
Pladevall-Morera et al. used a drug-screening strategy to show that ATRX-deficient high-grade glioma cells are more vulnerable to selected receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient cells. The study also found pronounced toxicity when RTK inhibition was combined with temozolomide, supporting ATRX status as a variable for interpreting targeted-therapy studies.
-
Chemerin–cNTS Redox Signaling and Blood Pressure
2026-09-04
The reference study identifies a chemerin–CMKLR1–NADPH oxidase–superoxide pathway in the caudal nucleus tractus solitarius that increases sympathetic nerve activity, arterial pressure, and heart rate. Its circuit-level pharmacology further places NMDA receptor signaling in the paraventricular nucleus downstream of caudal NTS chemerin, while CNQX-sensitive AMPA/kainate transmission was not required under the tested conditions.
-
Amorolfine Hydrochloride in Fungal Membrane Research
2026-09-03
Amorolfine Hydrochloride is a research-grade antifungal reagent for studying fungal cell membrane disruption and sterol-linked biology. Its defined solvent profile, storage requirement, and connection to yeast cell-integrity research support controlled mechanism studies, but the cited ploidy study does not directly test amorolfine.
-
FLCN Mutations and mRNA Rescue in BHD Syndrome
2026-09-03
A 2026 study identified a novel pathogenic FLCN nonsense variant and provided genetic and functional evidence that p.W376R is pathogenic in two Chinese Birt-Hogg-Dubé families. In HEK293T cells, synthetic FLCN mRNA restored FLCN expression and corrected abnormal mTORC1 signaling, offering an early but strictly in vitro rationale for mRNA-based protein replacement.
-
Catalpol, Sirt6, and Osteoclast Apoptosis
2026-09-02
This study identifies a Sirt6–ERα–FasL signaling mechanism through which catalpol reduces estrogen deficiency-associated bone loss in ovariectomized rats. By combining micro-CT, histology, osteoclast cell assays, gene silencing, and protein-interaction analysis, the work links catalpol treatment to enhanced osteoclast apoptosis rather than relying only on suppression of osteoclast differentiation.
-
PRMT5 Splicing Vulnerability in MYCN Neuroblastoma
2026-09-02
The reference study shows that MYCN-amplified neuroblastoma depends on PRMT5-regulated RNA splicing, with downstream disruption of epitranscriptomic control and glutamine metabolism. Its integrated transcriptomic, isotope-tracing, molecular, and in vivo experiments identify GLS regulation as a mechanistic link between spliceosomal stress and tumor-cell survival.
-
Laminin (925-933) for Reliable Cell Assays
2026-09-01
A scenario-based guide to using Laminin (925-933), SKU A1023, to control cell attachment, migration, and chemotaxis variables that can complicate viability and cytotoxicity assays. It covers formulation, concentration selection, controls, interpretation, and practical vendor evaluation.
-
PX-478 2HCl in Hypoxia Research
2026-08-31
PX-478 2HCl is a practical HIF-1α inhibition tool for paired normoxic–hypoxic cell assays, radiosensitization studies, tumor ischemia models, and prenatal hypoxia research. Its value is strongest when molecular target engagement is combined with functional, histological, or reporter-based readouts.
-
Beyond G1 Arrest: Translational Strategy for LEE011
2026-08-31
Ribociclib succinate is more than a tool for producing G1 arrest: it enables translational researchers to connect CDK4/6 biology with formulation control, orthogonal assay design, combination strategy, and biomarker-led decision-making. This article distinguishes established evidence from testable hypotheses and explains how LEE011 succinate can strengthen cancer research workflows beyond the scope of a conventional product page.
-
ICAA, RIP3, and Ang II Cardiac Hypertrophy
2026-08-30
The reference study identifies isochlorogenic acid A as a direct regulator of RIP3 that suppresses the RIP3/CaMKII axis during angiotensin II- and pressure overload-induced cardiac hypertrophy. Its most important advance is showing that RIP3 contributes to hypertrophic remodeling independently of MLKL, suggesting a mechanism distinct from canonical necroptosis.